EGFR mutation detection of lung circulating tumor cells using a multifunctional microfluidic chip

Yanmin Wang,Wanlei Gao,Man Wu,Xiaofen Zhang,Wei Liu,Yang Zhou,Chunping Jia,Hui Cong,Xiang Chen,Jianlong Zhao

DOI: https://doi.org/10.1016/j.talanta.2020.122057

IF: 6.1

2021-04-01

Talanta

Abstract:<p>Microfluidics has become a reliable platform for circulating tumor cells (CTCs) detection because of its high integration, small size, low consumption of reagents and rapid response. Here, we developed a multifunctional microfluidic device consists of three parts, including CTCs capture area, single-layer membrane valves area, and microcavity nucleic acid detection and analysis region based on digital polymerase chain reaction (dPCR), allowing CTCs capture, lysis, and genetic characterization to be performed on a single chip. The CTCs capture chip is coupled to the nucleic acid detection chip via a control valve. CTCs were firstly trapped in the CTC capture area, and then lysed using proteinase K to release nucleic acids. Subsequently CTCs lysate was transferred into nucleic acid detection area consisting of 12800 micro-cavity chambers for nucleic acids detection. To evaluate the performance of this chip, this study detected EGFR-L858R mutation in lung cancer cell lines H1975 and A549 cells, as well as leukocytes from normal donors. The results showed that positive signals were only observed in H1975 cells, and the detected value had a high linear relationship with the expected value (R² = 0.9897). In conclusion, this multi-functional microfluidic chip that integrates CTCs capture, lysis and nucleic acid detection can successfully detect gene mutations in CTCs, providing reference for tumor-targeted drugs and precise diagnosis and treatment.</p>

chemistry, analytical

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to develop a multifunctional microfluidic chip for efficiently capturing, lysing, and detecting EGFR gene mutations in lung cancer circulating tumor cells (CTCs). Specifically, the research aims to overcome the limitations of traditional tissue biopsy in monitoring tumor progression and provide a more convenient and efficient liquid biopsy method to achieve accurate diagnosis and treatment for lung cancer patients.

### Research Background

1. **High Incidence and Mortality of Lung Cancer**: Non - small - cell lung cancer (NSCLC) accounts for 75% - 85% of all lung cancers, and most patients are diagnosed at an advanced stage, resulting in an extremely low 5 - year survival rate (only 15%). The low early - diagnosis rate urgently requires new diagnostic tools.

2. **Importance of Circulating Tumor Cells (CTCs)**: CTCs are tumor cells that break off from the primary tumor or metastatic foci and enter the bloodstream. They are closely related to the occurrence and development of cancer and can be used as important biomarkers for monitoring tumor progression and metastasis.

3. **Significance of EGFR Mutations**: EGFR gene mutations are relatively common in NSCLC, especially the L858R mutation, which can promote the proliferation, invasion, and metastasis of tumor cells. Detecting these mutations is crucial for selecting targeted treatment regimens.

### Research Objectives

The main objective of this research is to develop a multifunctional microfluidic chip that integrates the functions of CTCs capture, lysis, and gene detection. Through this chip, the following tasks can be completed on a single platform:
- Capture CTCs in the blood.
- Lyse CTCs to release nucleic acids.
- Detect EGFR gene mutations using digital polymerase chain reaction (dPCR).

### Problems Solved

1. **Improve CTCs Capture Efficiency**: Traditional CTCs capture methods have problems such as low capture rate and complex operation. In this study, the CTCs capture efficiency was improved by designing a CTCs - enrichment area with a hexagonal pillar array and a filtering channel.

2. **Simplify the Operation Process**: Previous microfluidic chips usually required multiple steps to isolate and analyze CTCs, which were prone to cell loss or damage. In this study, the operation process was simplified and cell loss was reduced by integrating the functions of CTCs capture, lysis, and gene detection.

3. **Improve Detection Sensitivity**: By using dPCR technology, this chip can accurately detect a very small amount of EGFR mutations and has high sensitivity and specificity.

4. **Clinical Application Potential**: This chip is expected to become a valuable clinical tool for early diagnosis of lung cancer, selection of targeted drugs, and monitoring of treatment effects.

In conclusion, this research aims to develop an efficient and simple microfluidic chip that can achieve CTCs capture, lysis, and gene detection on a single platform, providing technical support for precision medicine in lung cancer.